Experimental Drug Therapies for the Treatment of Wet-Type Age-Related Macular Degeneration

Experimental medication therapy for the treatment of wet age-related macular degeneration presents a new therapeutic challenge to age-related diseases in the society where technology extends life expectancy. In the United States, elderly people aged 65 and over account for 21% of the population (US, 2001). As we get older, the perception system of the people of this group changes, making them difficult to function. Some of these changes occur systematically and naturally, but other changes will be caused by the disease.

Macular degeneration is a major cause of vision loss in people over the age of 60. Based on this there are two types: wet macular degeneration and dry macular degeneration. Moist macular degeneration is more advanced and accounts for 90% of severe vision loss. When someone suffers from moist macular degeneration, abnormal blood vessels appear under the retina and the macula. These abnormal blood vessels leak from the variety of liquids, sometimes bleeding, which can lead to mass macula. This lump completely destroyed the central vision of the person. Fortunately, a treatment was found in the early stages of wet macular degeneration. The top three are injection, photodynamic therapy, photocoagulation.

Experimental medication therapy for the treatment of wet age-related macular degeneration presents a new therapeutic challenge to age-related diseases in the society where technology extends life expectancy. In the United States, elderly people aged 65 and over account for 21% of the population (US, 2001). As we get older, the perception system of the people of this group changes, making them difficult to function. - Background Weight gain associated with antipsychotic treatment is one of the most important problems in the treatment of psychosis. In addition to causing self-esteem problems, it can also lead to serious health problems such as cardiovascular disease and premature death. 1 In fact, there is no effective medicine to promote weight loss in psychiatric patients. However, there are several studies showing that metformin may decrease metabolic rate.

Age-related macular degeneration is one of the most important causes of blindness in the elderly. As the population ages, the number of people affected will increase 2. There are two age-related macular degeneration. Geographical atrophy is a severely segmented pigmented area caused by atrophy of the retinal pigment epithelium and neovascular degeneration occurs when new blood vessels grow under the retinal pigment epithelium leading to bleeding and scar formation. Age-related macular degeneration is diagnosed in people over the age of 50 years, if there is no other obvious cause of degeneration.